UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~January~~February 429, 2008

MILLENNIUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware	0-28494	04-3177038
(State or other jurisdiction of incorporation)	(Commission file number)	(IRS Employer Identification No.)

40 Landsdowne Street
Cambridge, Massachusetts 02139
(Address of principal executive offices) (zip code)

(617) 679-7000
(Registrant's telephone number, including area code)

Not applicable
(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2 7.0201 Regulation ~~Results~~FD ~~of Operations and Financial Condition~~Disclosure.

~~On January 4, 2008,~~ Millennium Pharmaceuticals, Inc. ~~issued a press release to report selected unaudited financial~~(the ~~results~~“Company”) ~~for~~is ~~the~~providing ~~year ended December 31, 2007 and to provide~~ information about ~~its~~January ~~goals for~~ 2008. ~~The~~VELCADE® ~~full~~(bortezomib) for ~~text~~Injection ofU.S. ~~the~~sales ~~press~~data ~~release~~as isreported ~~attached~~by toIMS ~~this~~Health ~~Current~~Incorporated ~~Report~~(“IMS”) ~~on Form~~a 8third-Kparty aspharmaceutical ~~Exhibit~~information 99and consulting company.1.

~~The~~While ~~information~~the inCompany ~~this~~typically ~~Form~~does ~~8-K~~not ~~shall~~comment ~~not~~on beIMS ~~deemed~~sales ~~“filed”~~data, ~~for purposes of Section 18 of~~ the ~~Securities Exchange~~Company ~~Act~~believes ofit ~~1934~~is ~~(the~~important ~~“Exchange Act”) or otherwise subject~~ to remind the ~~liabilities~~ ofpublic that there ~~section,~~have ~~nor~~been ~~shall~~frequent itand besignificant ~~deemed~~discrepancies ~~incorporated~~in byIMS ~~reference~~data inrelative ~~any~~to actual ~~filing~~VELCADE ~~under~~sales. ~~the~~The ~~Securities~~Company ~~Act~~has ofnoted ~~1933~~these ordiscrepancies ~~the~~on ~~Exchange~~a ~~Act,~~monthly ~~except~~and asquarterly ~~expressly~~basis, both ~~set~~in ~~forth by~~terms ~~specific~~of ~~reference~~direction inand ~~such~~magnitude aof ~~filing~~change.

The ~~attached~~Company ~~press~~is ~~release~~also ~~contains~~confirming ~~non-GAAP~~its 2008 ~~financial~~VELCADE ~~measures~~U.S. ~~These~~net ~~non-GAAP~~sales ~~measures~~guidance ~~should~~of be$320 ~~considered~~million into ~~addition~~$345 tomillion, ~~not~~representing ~~as a~~20 ~~substitute~~percent ~~for~~to 30 percent growth over 2007, oras ~~superior~~originally stated in January 2008. The Company also wishes to ~~other~~notify ~~measures~~the ofpublic that the ~~Company’s~~growth ~~financial~~drivers ~~position~~that accelerated VELCADE U.S. ~~prepared~~sales in ~~accordance~~2007 ~~with~~continue ~~generally~~to ~~accepted~~drive ~~accounting~~growth ~~principles~~in ~~(GAAP)~~VELCADE demand in 2008.

~~Specifically~~This Form 8-k contains “forward-looking statements,” including statements about the ~~attached~~Company’s growth ~~press~~and development of products. Various important risks may cause the Company’s ~~release~~actual ~~discusses~~results ~~non-GAAP~~to ~~net~~differ ~~income,~~materially ~~non~~from the results indicated by these forward-~~GAAP~~looking statements, ~~research~~including: adverse results in its drug discovery and clinical development programs; ~~expenses~~failure ~~and~~to obtain patent protection for its discoveries; commercial limitations ~~non-GAAP~~imposed ~~selling,~~by ~~general~~patents ~~and~~owned ~~administrative~~or ~~expenses~~controlled ~~which~~by ~~are~~third ~~non-GAAP~~parties; ~~financial~~the Company’s dependence ~~measures.~~upon ~~With~~strategic ~~respect~~alliance partners to ~~forward-looking~~develop ~~information~~and ~~presented~~commercialize onproducts aand ~~non-GAAP~~services ~~basis, other~~based ~~than~~on ~~amortization~~its ~~expenses~~work; ofdifficulties ~~$34~~or ~~million~~delays in ~~2008,~~obtaining ~~restructuring~~regulatory ~~charges~~approvals ofto market products ~~less~~and ~~than~~services $5resulting ~~million~~from its development efforts; product withdrawals; competitive factors; difficulties or delays in ~~2008~~manufacturing the Company’s products; government and ~~stock~~third-~~based~~party ~~compensation~~reimbursement ~~expense~~rates; the commercial success of ~~approximately~~VELCADE ~~$30~~and INTEGRILIN® ~~million~~(eptifibatide) inInjection; ~~2008,~~achieving revenue consistent with internal forecasts; and the requirement ~~Company~~for issubstantial ~~unable~~funding to ~~provide~~conduct research and development and to expand commercialization activities. For a ~~quantitative~~further ~~reconciliation~~list ~~because~~and description of the risks and uncertainties the ~~items~~Company ~~that~~faces, ~~would~~see bethe ~~excluded~~reports ~~are~~it ~~difficult~~has tofiled ~~predict~~with ~~and~~the ~~estimate~~Securities and Exchange ~~are~~Commission. ~~primarily~~The Company disclaims any intention or obligation to update or revise ~~dependent~~any onforward- looking statements, whether as a result of new information, future events or otherwise.

The ~~Company’s~~information ~~management~~in ~~uses these~~this ~~non-GAAP~~Item ~~financial measures to supplement its understanding of the Company’s~~7.01 ~~core~~shall ~~operating~~not ~~results~~be ~~and~~deemed ~~future~~filed ~~prospects,~~for ~~consistent~~purposes ~~with~~of ~~how~~Section ~~management measures and~~18 ~~forecasts~~of the ~~Company’s~~Securities ~~performance,~~Exchange ~~especially~~Act ~~when~~of ~~comparing~~1934 ~~such~~(the ~~results~~“Exchange ~~to previous~~Act”) ~~periods~~ or ~~forecasts~~otherwise or subject to ~~those of~~ the ~~Company’s~~liabilities ~~competitors.~~of ~~These measures~~that ~~are~~section, ~~also~~nor ~~used~~shall byit ~~the~~be ~~Company’s~~deemed ~~management~~incorporated inby ~~their~~reference ~~financial and operating~~in ~~decision-making~~any ~~and~~filing ~~for~~under ~~compensation~~the ~~purposes.~~Securities ~~For~~Act ~~example, while Company managers are held accountable for most aspects~~ of ~~compensation~~1933 ~~expense~~or ~~within~~the ~~departmental~~Exchange ~~budgets~~Act, ~~stock-based~~ ~~compensation~~except ~~expense~~as isexpressly ~~not included in the internal development, tracking or~~set ~~evaluation~~forth ofby ~~departmental~~specific ~~budgets~~reference asin ~~reviewed~~such bya ~~senior management~~filing.

These non-GAAP measures exclude certain non-operational and restructuring charges, non-cash charges and specified other charges that are included in the most directly comparable GAAP measures. The Company excludes these items to facilitate comparisons to historical operating results. The Company believes that excluding these charges provides the users of financial statements with important insight into the Company’s operating results and related trends and provides the users the opportunity to understand and analyze the Company’s results in a manner consistent with how management analyzes the results. Specifically, on both a historic and a forward-looking basis, these non-GAAP measures exclude:

	•		Expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of two to 13 years. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both the Company’s newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.
	•		Costs associated with the Company’s restructuring efforts, such as reducing overhead and consolidating facilities, resulting from the restructured relationship between Schering-Plough and the Company for INTEGRILIN® (eptifibatide) Injection and the reduction in the Company’s in-house research and development technologies and personnel as well as associated general and administrative personnel and expenses. The Company believes that the costs related to these restructuring activities are not indicative of the Company’s normal operating costs.

	•		Expense associated with stock-based compensation related to stock options, the Company’s employee stock purchase plan and restricted stock because, while stock-based compensation is a significant ongoing expense affecting the Company’s results of operations, the Company’s management excludes stock-based compensation from the Company’s forecasting and planning process used to allocate resources in the Company’s ongoing portfolio prioritization efforts. Additionally, the Company believes that excluding this expense could be helpful in comparing the Company’s financial results to periods prior to January 1, 2006 because stock-based compensation charges are excluded in the various operating expense categories. Finally, because of varying available valuation methodologies, subjective assumptions and the variety of award types, the Company believes that excluding stock-based compensation may enable useful comparisons of the Company’s operating results to its competitors.
	•		Termination payment, net of transaction expenses, associated with the Company’s receipt of a one-time payment resulting from the Company and AnorMED Inc.‘s mutual agreement to terminate the Support Agreement between the parties. The Company believes that the gain related to the termination fee received from AnorMED is not indicative of the Company’s normal revenues generated from its core operations.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MILLENNIUM PHARMACEUTICALS, INC.(Registrant)
Date: January 4, 2008	By	/s/ MARSHA H. FANUCCI
Date: February 29, 2008	By	/s/ MARSHA H. FANUCCI
		Marsha H. Fanucci
		Senior Vice President and Chief Financial Officer

EXHIBIT INDEX

Exhibit No.			Description
	99.1		Press Release of Millennium Pharmaceuticals, Inc. dated January 4, 2008

Filing Compare · MILLENNIUM PHARMACEUTICALS INC